Study of RPTR-1-201 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that cannot be removed by surgery or cured with current treatments.
- Your tumor can be measured on scans (at least one spot that can be tracked).
- You are able to take care of yourself (ECOG score 0 or 1).
- Your organs (like liver, kidneys, and bone marrow) are working well enough.
- You have not had another type of cancer in the last 3 years, except for certain minor skin cancers or early-stage cancers that are considered cured.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called PLT012 for people with advanced solid tumors. It is the first study in humans, so doctors will see if the drug is safe and how the body handles it.
This study tests a new medicine called IPN01195 for adults with advanced solid tumors that have a specific genetic change (MAPK pathway). It aims to see if the drug is safe and works against these cancers when other treatments are no longer working.
This trial tests an investigational drug called RP-001 in people with advanced solid tumors. It aims to see if RP-001 can help when given alone, especially in cancers that may respond to a class of chemotherapy called taxanes, or in pancreatic or colorectal cancer that has returned or not responded to prior treatment.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
This study tests a new drug, CRB-601-01, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and can help shrink tumors.
Hear when a new Advanced Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.